論 文
＜欧文＞
1. Kawabe A, Tsujimura S, Saito K, Tanaka Y.
Efficacy of Intravenous Cyclophosphamide Pulse Therapy for P-Glycoprotein-expressing B Cell-associated Active True Renal Lupus Vasculitis in Lupus Nephritis.
Internal Med (2017) 56, 1575-1580
2. Nakano K, Aritomi T, Okubo N, Tanaka Y.
Relapsing polychondritis diagnosed by fusion images of gallium-67 on single photon emission computed tomography/computed tomography.
Arthritis Rheum (2017) 69, 2406
3. Tanaka K, Okada Y, Mori H, Torimoto K, Arao T, Tanaka Y.
Effects of mitiglinide and repaglinide on postprandial hyperglycemia in patients undergoing methylprednisolone pulse therapy.
Internal Med (2018)57,65-70
4. Koikawa K, Okada Y, Mori H, Kawaguchi M, Uchino S, Tanaka Y.
A case of hyperparathyroidism-jaw tumor syndrome confirmed by preoperative genetic testing. Internal Med (2018)57,841-844
5. Kubo S, Nakayamada S, Yoshikawa M, Miyazaki Y, Sakata K, Nakano K, Hanami K, Iwata S, Miyagawa I, Saito K, Tanaka Y.
Peripheral immunophenotyping identifies three subgroups based on T cell heterogeneity in lupus patients. Arthritis & rheumatology (Hoboken, N.J.) (2017)2029-2037
6. Sato Y, Nakano K, Yoshinari H, Nakayamada S, Iwata S, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Saito K, Tanaka Y.
A Case of Refractory Lupus Nephritis Complicated by Psoriasis Vulgaris That Was Controlled with Secukinumab. Lupus (2018)
7. Sato Y, Nakano K, Yoshinari H, Nakayamada S, Iwata S, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Saito K, Tanaka Y.
A Case of Refractory Lupus Nephritis Complicated by Psoriasis Vulgaris That Was Controlled with Secukinumab. Lupus (2018)
8. Tanaka Y, Kubo S, Iwata S, Yoshikawa M, Nakayamada S.
B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus. Clinical Immunology (2017) pii:S1521-6616(17)30537-5
9. Kubo S, Nakayamada S, Nakano K, Sawamukai N, Hirata S, Hanami K, Saito K, Tanaka Y.
Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching.
Clinical immunology (2017)191,67-74
10. Torimoto K, Okada Y, Koikawa K, Tanaka Y.
Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring.
Diabetology & metabolic syndrome (2017)9,60
11.Torimoto K, Okada Y, Kurozumi A, Narisawa M, Arao T, Tanaka Y.
Clinical Features of Patients with Basedow's Disease and High Serum IgG4 Levels. Internal medicine (2017)56,1009-1013
12. Mori H, Okada Y, Tanaka Y.
The Effects of Pioglitazone on Bone Formation and Resorption Markers in Type 2 Diabetes Mellitus. Internal medicine. (2018)56,1301-1306
13. Kurozumi A, Okada Y, Arao T, Kobayashi T, Masuda D, Yamashita S, Tanaka Y.
Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients. Journal of diabetes investigation (2018)9,360-365
14. Hajime M, Okada Y, Mori H, Otsuka T, Kawaguchi M, Miyazaki M, Kuno F, Sugai K, Sonoda S, Tanaka K, Kurozumi A, Narisawa M, Torimoto K, Arao T, Tanaka Y.
Twenty-four-hour variations in blood glucose level in Japanese type 2 diabetes patients based on continuous glucose monitoring.
Journal of diabetes investigation (2018) 9,75-82
15.Torimoto K, Okada Y, Sugino S, Tanaka Y.
Determinants of hemoglobin A1c level in patients with type 2 diabetes after in-hospital diabetes education: A study based on continuous glucose monitoring.
16. Miyagawa I, Nakayamada S, Nakano K, Yamagata K, Sakata K, Yamaoka K, Tanaka Y.
Induction of Regulatory T Cells and Its Regulation with Insulin-like Growth Factor/Insulin-like Growth Factor Binding Protein-4 by Human Mesenchymal Stem Cells.
Journal of diabetes investigation (2017)199,1616-1625
17. Torigoe M, Iwata S, Nakayamada S, Sakata K, Zhang M, Hajime M, Miyazaki Y, Narisawa M, Ishii K, Tanaka Y. Metabolic Reprogramming Commits Differentiation of Human CD27+IgD+ B Cells to Plasmablasts or CD27-IgD- Cells.
Journal of immunology (2017)199,425-434
18. Yoshinari H, Saito K, Nakano K, Fukuyo S, Miyagawa I, Tanaka Y.
A case of rheumatoid arthritis treated with infliximab who developed disseminated Penicillium marneffei infection after visit to Thailand.
Mod Rheumatol Case Reports (2017)43-48
19. Tanaka Y, Ohira T.
Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system. Curr Opin Pharmacol. (2018)940,110-119
20. Miyagawa I, Nakayamada S, Nakano K, Kubo S, Iwata S, Miyazaki Y, Yoshikawa M, Yoshinari H, Tanaka Y. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis.
Rheumatology (Oxford). (2018) in press
21. Kubo S, Nakayamada S, Nakano K, Sawamukai N, Hirata K, Saito K, Tanaka Y.
Conparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching.
Clin Immunol. (2018) 191,67-74
22. Kakugawa T, Sakamoto N, Ishimoto H, Shimizu T, Nakamura H, Nawata A, Ito S, Hanaka T, Oda K, Kido T, Miyamura T, Nakashima S, Aoki T, Nakamichi S, Obase Y, Saito K, Saito K, Yatera K, Ishimatsu Y, Nakayama T, Korogi Y, Kawakami A, Tanaka Y Mukae H.
Lymphocytic focus score is positively related to airway and interstitial lung diseases in primary Sjogren’s syndrome.
Respir Med. (2018) 137,95-102
23. Yamagata K, Nakayamada S, Tanaka Y.
Use of mesenchymal stem cells seeded on the scaffold in articular cartilage repair. Inflamm Regen. (2018) 38: 4
24. Sonoda S, Okada Y, Mori H, Uemura F, Sugai K, Hajime M, Tanaka K, Kurozumi A, Narisawa M, Torimoto K, Tanaka Y.
Association Between Diabetic Microangiopathies and Glycemic Variability Assessed by Continuous Glucose Monitoring
J UOEH. (2018) 40,11-18
25. Kurozumi A, Okada Y, Sugai K, Torimoto K, Tanaka Y.
Comparison of the Effects of Teneligliptin, and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with Different Half-Lives, on Glucose Fluctuation and Glucagon-Like Peptide-1 in Type 2 Diabetes Mellitus.
J UOEH. (2018) 40,1-9
26. Miyata M, Kakeda S, Kudo K, Iwata S, Tanaka Y, Wang Y, Korogi Y.
Evaluation of oxygen extraction fraction in systemic lupus erythematosus patients using quantitative susceptibility mapping.
J Cereb Blood Flow Metab. (2018) 1,271678X18764829
27. Tanaka Y, Takeuchi T, Harigai M, Yamanaka H, Nakano T, Akagi K, Ukyo Y, Hsu B.
Efficacy and safety of sirukumab in Japanese patients with active rtheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T).
Mod Rheumatol. (2018) 13,1-8
28. Nagayasu A, Kubo S, Nakano K, Nakayamada S, Iwata S, Miyagawa I, Fukuyo S, Saito K, Tanaka Y. lgG4-related Pleuritis with Elevated Adenosine Deaminase in Pleural Effusion: A Case Report. Intern Med. (2018), in press
29. Takeuchi T, Yamanaka H, Harigai M, Tamamura R, Kato Y, Ukyo Y, Nakano T, Hsu B, Tanaka Y.
Sirukumab in rtheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients.
Arthritis Res Ther. (2018) 20,42
30. Tuttle KR, Brosius FC 3rd, Adler SG, Kretzler M, Mehta RL, Tumlin JA, Tanaka Y, Haneda M, Liu J, Silk ME, Cardillo TE, Duffin KL, Haas JV, Macias WL, Nunes FP, Janes JM.
JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.
Nephrol Dial Transplant. (2018), in press
31. Ide S, Kakeda S, Miyata M, Iwata S, Ohkubo N, Nakayamada S, Futatsuya K, Watanabe K, Moriya J, Fujino Y, Tanaka Y, Korogi Y.
Intracranial vessel wall lesions in patients with systematic lupus erythematosus. J Magn Reson Imaging. (2018), in press
32. Gudmann NS, Hirata S, Karsdal MA, Kubo S, Bay-Jensen AC, Tanaka Y.
Increased remodelling of interstitial collagens and basement membrane is suppressed by treatment in patients with rheumatoid arthritis: serological evaluation of a one-year prospective study of 149 Japanese patients. Clin Exp Rheumatol. (2018), in press
33. Sumida T, Azuma N, Moriyama M, Takahashi H, Asashima H, Honda F, Abe S, Ono Y, Hirota T, Hirata S, Tanaka Y, Shimizu T, Nakamura H, Kawakami A, Sano H, Ogawa Y, Tsubota K, Ryo K, Saito I, Tanaka A, Nakamura S, Takamura E, Tanaka M, Suzuki K, Rakeuchi T, Yamakawa N, Mimori T, Ohta A, Nishiyama S, Yoshihara T, Suzuki Y, Kawano M,Tomiita M, Tsuboi H.
Clinical practice guideline for Sjogren’s syndrome 2017. Mod Rheumatol (2018) 28,383-408
34. Ishii T, Tanaka Y, Kawakami A, Saito K, Ichinose K, Fujii H, Shirota Y, Shirai T, Fujita Y, Watanabe R, Chiu SW, Yamaguchi T, Harigae H.
Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus.
Mod Rheumatol. (2018), in press
35. Takeuchi T, Tanaka Y, Yamanaka H, Harigai M, Nakano T, Akagi K, Ukyo Y, Hsu B.
Efficacy and safety of sirukumab in Japanese patients with moderate to severe rtheumatoid arthrtis inadequately controlled by disease modifying anti-rtheumatic drugs:Subgroup analysis of a phasse 3 study.
Mod Rheumatol. (2018), in press
36. Kochi Y, Kamatani Y, Kondo Y, Suzuki A, Kawakami E, Hiwa R, Momozawa Y, Fuimoto M, Jinnin M, Tanaka Y, Kanda T, Cooper RG, Chinoy H, Rothwell S, Lamb JA, Vencovsky J, Mann H, Ohmura K, Myouzen K, Ishigaki K, Nakashima R, Hosono Y, Tsuboi H, Kawasumi H, Iwasaki Y, Kajiyama H , Horita T, Ogawa-Momohara M, Takamura A, Tsunoda S, Shimizu J, Fujio K, Amano H, Mimori A, Kawakami A, Umehara H, Takeuchi T, Sano H, Muro Y, Atsumi T, Miura T, Kawaguchi Y, Mimori T, Takahashi A, Kubo M, Kohsaka H, Sumida T, Yamamoto K.
Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Ann Rheum Dis. (2018) 77,602-611
37. Zang F, Bae SC Bass D, Chu M, Eggginton S, Gordon D, Roth DA, Zheng J, Tanaka Y.
A pivotal phase lll, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
38. Uemura F, Okada Y, Torimoto K, Tanaka Y.
Relation Between Hypoglycemia and Glycemic Variability in Type 2 Diabetes Patients with Insulin Therapy: A Study Based on Continuous Glucose Monitoring.
Diabetes Technol Ther. (2018), 20,140-146
39. Kaneko Y, Takeuchi T, Cai Z, SatoM, Awakura K, Gaich C, Zhu B, Guo J, Tanaka Y.
Determinants of Patient’s Global Assessment of Disease Activity and Physician’s Global Assessment of Disease Activity in patients with rheumatoid arthritis: A post hoc analysis of overall and Japanese results from phase 3 clinical trials.
Mod Rheumatol. (2018), in press
40. Ishiguro N, Dougados M, Cai Z, Zhu B, Ishida M, Sato M, Gaich C, Quebe A, Stoykov I, Tanaka Y,
Relationship between disease activity and patient-reported outcomes in rtheumatoid arthritis: Post hoc analyses of overall and Japanese results from two phase 3 clinical trials.
Mod Rheumatol. (2018), in press
41. Kubo S, Nakayamada S, Zhao J, Yoshikawa M, Miyazaki Y, Nawata A, Hirata S, Nakano K, Saito K, Tanaka Y. Correlation of T follicular helper cells and plasmablasts with the development of organ involvement in patients with lgG4-related disease.
Rheumatology (Oxford). (2018)57, 514-524
42. Nawata A, Hisano S, Shimajiri S, Wang KY, Tanaka Y, Nakayama T.
Podocyte and endothelial cell injury lead to nephrotic syndrome in proliferative lupus nephritis. Histopathology. 2018, in press
43. Takeuchi T, Harigai M, Tanaka Y, Yamanaka H, Ishiguro N, Yamamoto K, Miyasaka N, Koike T, Ukyo Y, Ishii Y, Yoshinari T, Baker D; Go-MONO study group.
Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120.
Mod Rheumatol. 2018, in press
44. Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, Nomura A, Yoshida S, Nishimoto N. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).
Ann Rheum Dis. (2018) 77,348-354
Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.
Mod Rheumatol. 2018, in press
46. Oku K, Atsumi T, Akiyama Y, Amano H, Azuma N, Bohgaki T, Asanuma YF, Horita T, Hosoya T, Ichinose K, Kato M, Katsumata Y, Kawaguchi Y, Kawakami A, Koga T, Kohsaka H, Kondo Y, Kubo K, Kuwana M, Mimori A,Mimori T, Mimura T, Murakami K, Nakano K, Nakayamada S, Ogishima H, Ohmura K, Saito K, Sano H, Shibuya M, Takahashi Y, Takasaki Y, Takeuchi T, Tamura N, Tanaka Y, Tsuboi H, Tsunoda S, Yukawa N, Yamakawa N, Yamamoto K, Sumida T.
Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC).
Mod Rheumatol. 2018, in press
47. Tanaka S, Tanaka Y, Ishiguro N, Yamanaka H, Takeuchi T.
RANKL: A therapeutic target for bone destruction in rtheumatoid arthritis. Mod Rheumatol. (2018) 28,9-16
48. Fleischmann R, Kremer J, Tanaka Y, Grube D, Kanik K, Koncz T, Krishnaswami S, Wallenstein G, Wilkinson G, Zwillich S, Keystone E.
Efficacy and safety of tofacitinib in patients with active rtheumatoid arthritis: review of key phase 2 studies. Int J Pheum Dis (2016) 19, 1216-1225
49. Tanaka Y.
Intorducing the launch of Modern Rheumatology Case Reports. Mod Rheumatol Case Reports (2017) 1,1-1
50. Keystone EC, Taylor PC, Tanaka Y, Gaich C, DeLozier AM, Dudek A, Zamora JV, Cobos JAC, Rooney T, de Bono S, Arora V, Linetzky B, Weinblatt ME.
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis.
Ann Rheum Dis (2017) 76, 1853-1861
51. Tsujimura S, Adachi T, Saito K, Tanaka Y.
Role of P-glycoprotein on CD69+CD4+ cells in the pathogenesis of proliferative lupus nephritis and non-responsiveness to immunosuppressive therapy.
RMD Open. 2017 Jul 14;3(1):e000423
52. Sakamoto Y, Yamamoto T, Sugano N, Takahashi D, Watanabe T, Atsumi T, Nakamura J, Hasegawa Y, Akashi K, Narita I, Miyamoto T, Takeuchi T, Ikari K, Amano K, Fujie A, Kubo T, Tada Y, Kaneuji A, Nakamura H,
Miyamura T, Kabata T, Yamaji K, Okawa T, Sudo A, Ohzono K, Tanaka Y, Yasunaga Y, Matsuda S, Imai Y; Japanese Research Committee on Idiopathic Osteonecrosis of the Fermoral Head, Akiyama M, Kubo M, Kamatani Y, Iwamoto Y, Ikegawa S.
Genome-wide Association Study of Idiopathic Osteonecrosis of the Femoral Head. Sci Rep.2017 Nov 8;7(1):15035
53. Tsuboi H, Hagiwara S, Asashima H, Takahashi H, Hirota T, Noma H, Umehara H, Kawasami A, Nakamura H, Sano H, Tsubota K, Ogawa Y, Takamura E, Saito I, Inoue H, Nakamura S, Moriya M, Takeuchi T, Tanaka Y, Hirata S, Minori T, Matsumoto I, Sumida T.
Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjogren’s syndrome with other sets of criteria in Japanese patients.
Ann Rheum Dis 76: 1980-1985
54. Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, del Camen Morales L, Gonzaga JR, Yakushin s, Ishii T, Emoto K, Veatie S, Arora V, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y.
Baricitinib versus placebo or adalimumab in rheumatoid arthritis. New Engl J Med (2017) 375,652-662
55. Tanaka Y, Yamanaka H, Takeuchi T, Inoue M, Saito K, Saeki Y, Lee SJ, Nambu Y.
Safety and efficacy of CT-P13 in Japanese patients with rtheumatoid arthritis in an extension phase or after switching from infliximab.
Mod Rheumatol (2017) 27, 237-245
56. Tanaka Y, Takeuchi T, Akashi N, Takita Y, Kovacs B, Kariyasu S.
Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus; subgroup analyses of the ILLUMINATE-1 stydy.
Mod Theumatol (2017) 27,284-291
57. Ishiguro N, Atsumi T, Harigai M, Mimori T, Nishimoto N, Sumida T, Takeuchi T, Tanaka Y, Nakasone A, Takagi N, and Yamanaka H.
Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio Study.
Mod Rheumatol (2017) 27, 217-226
58. Mori H, Okada Y, Kurozumi A, Narisawa M, Tanaka Y.
Factors influencing inter-day glycemic variability in diabetic outpatients on insulin therapy. J Diabetes Invest (2017) 8, 69-74
59. Tanaka K, Okada Y, Mori H, Miyazaki M, Kuno F, Sonoda S, Sugai K, Hjime M, Kurozumi A, Narisawa M, Torimoto K, Arao T, Mine S, Tanaka Y.
Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus. Endocrine J (2017) 64, 179-189
60. Tanaka T, Yamanaka H, Ishiguro N, Miyasaka N, Kawana K, Kimura J, Agata N, Takeuchi T.
Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rtheumatoid arthritis: 2-years results of the HOPEFUL-3 Study.
Arthritis Res Ther (2017) 19:56
61. Arao T, Okada Y, Torimoto K, Sugai K, Otsuka T, Kurozumi A, Tanaka Y.
Comparison between effectiveness of 100 mg/day sitagliption and a switch to mitiglinide calcium hydrate/voglibose from 50 mg/ day sitagliption in patients with type 2 diabetes.
J OUEH (2017)
62. Aletaha D, Bingham III Co, Tanaka Y, Agarwal P, Kurrasch R, Tak PP, Popik S.
Efficacy and safety of sirukumab, an anti-IL-6 cytokine monoclonal antibody , in patients with active rtheumatoid arthritis despite anti-TNF therapy: results from the randomized, double-blind, placebo-controlled, global, phase 3 SIRROUND-T study.
Loncet (2017) 389,1206-1217340.
63. Tanaka K, Okada Y, Mori H, Inada Y, Suzuka K, Uriu K, Tanaka Y.
Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic 5 patients with chronic kidney disease, Assessment by continuous glucose monitoring-a pilot study-.
Diabetology Intermational (2017) 64: 179-189
64. Takeuchi T, Nakajima R, Komatsu S, Yamazaki K, Nakamura T, Agata N, Igarashi A, Tango T, Tanaka Y. Impact of adalimumab on work productivity and activity impairment in Japanese patients with rheumatoid arthritis: large-scale, prospective, single-cohort
ANOUVEAU study. Adv Ther (2017) 34:686-702
65. Fukuyo S, Nakayamada S, Iwata S, Kubo S, Saito K, Tanaka Y.
Abatacept therapy reduces CD28⁺CXCR5⁺ follicular helper like T cells in patients with rheumatoid arthritis. Clin Exp Rheumatol (2017) 35:562-570
66. Mori H, Okada Y, Tanaka Y.
Effects of pioglitazone on bone formation and resorption markers in type 2 diabetes mellitus. Internal Medicine (2017) 56: 1301-1306
67. Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KI, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J.
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
Ann Rheum Dis (2017) 76: 1253-1262
68. Atsumi T, Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Wada A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Togo O, Okada T, van der Heijde D, Miyasaka N, Koike T.
Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a pjase III randomized trial.
Ann Rheum Dis (2017) 76: 1348-1356
69. Kubo S, Yamaoka K, Amano K, Ngano S, Tomas S, Suematsu E, Nagasawa H, Iwata K, Tanaka Y.
Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: A prospective, multicenter, observational study.
Rheumatology (2017) 56,1293-1301
70. Oba K, Horie N, Sato K, Saito K, Takeuchi T, Mimori T, Miyasaka N, Koike T, Tanaka Y, Remission Induction by Raising the dose of remicade in RA (RRRR) study: rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis.
Contemporary Clinical Trials Communications (2017) 8, 49-54
71. Masaki Y, Matsui S, Saeki T, Tsuboi H, Hirata S, Izumi Y, Miyashita T, Fujikawa K, Dobashi H, Susaki K, Morimoto H, Takagi K, Kawano M, Origuchi T, Wada Y, Takahashi N, Horikoshi M, Ogishima H, Suzuki Y, Kawanami T, Kawanami HI, Sakai T, Fujita Y, Fukushima T, Saito M, Suzuki R, Morikawa Y, Yoshino T, Nakamra S, Kojima M, Kurose N, Sato Y, Tanaka Y, Sugai S, Sumida T.
A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated lgG4-related disease. Mod Rheumatol (2017) 27, 849-854
72. Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez , Hirose T, Nduaka CI, Wang L, Mendelsohn AM, Fan H, Chen C, Bananis E.
Horpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. Arthritis Rheum (2017) 69, 1960-1968
73. Torimoto K, Okada Y, Nakayamada S, Kubo S, Tanaka Y.
cells.
Thyroid (2017) 27, 1335-1336
74. Miyata M, Kakeda S, Iwata S, Nakayamada S, Ide S, Watanabe K, Moriya J, Tanaka Y, Korogi Y. Enlarged perivascular spaces are associated with the disease activity in systemic lupus erythematosus. Sci Rep (2017) 7:12566
75. Kawabe A, Tsujimura S, Saito K, Tanaka Y.
Successful switch to golimumab for eosinophilia and skin symptoms related to multiple biologics in an patient with rheumatoid arthritis.
Internal Med (2017) 56: 1575-158
76. Ishikawa Y, Miyagawa I, Nakano K, Saito Y, Todoroki Y, Kubo S, Nawata A, Nkayamada S, Saito K, Tanaka Y. The occurrence of hypertrophic pachymeningitis with infiltration of lgG4-positive plasma cell and with different etiology: Report of three cases.
Mod Rheumatol Case Reports (2017) 1, 43-48
77. Kawabe A, Nakano K, Aiko Y, Aramaki S, Onoue T, Okura D, Tanaka Y.
Successful management of pregnancy in a patient with systemic lupus erythematosus-associated pulmonary arterial hypertensiony.
Internal Med (2017) 56, 1575-1580
78. Arao T, Okada Y, Uemura F, Nishizawa S, Tanaka Y.
A Case of Acromegaly in which a Pituitary Gland Tumor was Reduced Significantly by Administering Octreotide Long Acting Release (LAR) and Could Be Removed Surgically.
J UOEH (2017) 39: 241-2456
79. Kawabe A, Tsujimura S, Saito K, Tanaka Y.
Efficacy of Intravenous Cyclophosphamide Pulse Therapy for P-Glycoprotein-expressing B Cell-associated Active True Renal Lupus Vasculitis in Lupus Nephritis.
Internal Med (2017) 56,1575-1580
80. Tanaka A, Shimabukuro M, Okada Y, Taguchi I, Yamaoka-Tojo M, Tomiyama H, Teragawa H, Sugiyama S, Yoshida H, Sato Y, Kawaguchi A, Ikehara Y, Machii N, Maruhashi T, Shima K, Takamura T, Matsuzawa Y, Kimura K, Sakuma M, Oyama J, Inoue T, Higashi Y, Ueda S, Node K:Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
81. Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Umayahara Y, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ohashi M, Taki H, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I; UTOPIA study investigators.: Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative study.
Diabetes Ther 8: 999-1013,2017
82. Kurozumi A, Okada Y, Satoh H, Inoue I, Chimori H, Akita E, Shiraiwa T, Fujitani Y, Mita T, Gosho M, Watada H: Effects of linagliptin monotherapy compared with voglibose on postprandial lipid profiles in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP) sub -study 1. Endocrine J (in press)
83. Goto H, Mita T, Fujitani Y, Fujimoto S, Takahashi K, Satoh H, Hirose T, Hiyoshi T, Ai M, Okada Y, Nishimura H, Kuroda H, Matsubara T, Gosho M, Ishii H, Watada H: Effects of linagliptin versus voglibose on treatment- related quality of life in patients with type 2 diabetes: sub-analysis of the L-STEP study.
Endocrine J (in press)
84. Iwata S, Saito K, Hirata S, Ohkubo N, Nakayamada S, Nakano K, Hanami K, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Yoshinari H, Tanaka Y.
Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. Lupus. 2018 Jan 1:961203317749047. doi: 10.1177/0961203317749047. [Epub ahead of print]
＜邦文＞
1. 田中良哉 関節リウマチの薬物療法 医学と薬学（2017）74, 19-28 2. 田中良哉 関節リウマチへの早期積極的治療介入と treatment holiday CLINICIAN（2017） 654, 62-67 3. 中野和久、田中良哉 関節リウマチ滑膜における DNA メチル化と TET 分子 Keynote RA （2017） 5, 9-13 4. 中山田真吾、田中良哉 全身性エリテマトーデスにおける免疫異常のオーバービュー炎症と免疫 (2017) 25, 120-124 5. 田中良哉 バイオシミラーの現状 Mebio (2017) 34, 54-61 6. 田中良哉 ステロイド性骨粗鬆症 腎と骨代謝 (2017) 30, 123-128 7. 久保智史、中山田真吾、田中良哉 関節リウマチ治療におけるバリシチニブの有用性 リウマチ科 (2017) 57, 410-415 8. 田中良哉 日本のリウマチ学が世界に評価されつづけるには 臨床リウマチ (2017) 29, 1-4 9. 田中良哉 関節リウマチに対する分子標的薬の新展開 臨床免疫・アレルギー科 (2017) 68, 64-71 10. 田中良哉 ステロイドの副作用管理のポイント 臨床と研究 (2017) 94, 855-858 11. 田中良哉
Multi-biomarker disease activity (MBDA)は関節リウマチの疾患活動性を正確に反映するか リウマチ科 (2017) 58, 63-68
12. 田中良哉
骨髄由来間葉系幹細胞を用いた骨関節疾患治療 THE BONE（2017）31, 211-216
13. 久保智史、田中良哉
CORRONA レジストリーのアバタセプトとトシリズマブの comprative effectiveness study リウマチ科 (2017) 58, 441-445
JAK 阻害薬の開発の現状と今後の展望 リウマチ科 (2017) 58, 452-560 15. 田中良哉 期待される血管炎の新規治療 呼吸器内科 (2017) 32, 375-379 16. 中山田真吾、田中良哉 バリシチニブ 分子リウマチ治療 (2017) 10, 197-201 17. 久保智史、田中良哉 関節の MRI の診かた 分子リウマチ治療 (2017) 47, 1089-1093 18. 田中良哉
JAK 研究 UPDATE: JAK 阻害薬に迫る Joint and Kinase Frontier (2017) 1, 2-3
19. 田中良哉 ステロイド過剰と骨リモデリング異常 CLINICAL CALCIUM （2017） 27, 1731-1738 20. 田中良哉 バイオシミラーの開発の現状と未来 リウマチ科 (2017) 58, 607-613 21. 久保智史、田中良哉 強皮症 リウマチ科 (2018) 59, 27-32 22. 田中良哉 ステロイド性骨粗鬆症 日本医師会雑誌 (2018) 146, 2045-2048 23. 田中良哉、遠藤直人、杉本利嗣、伊東昌子 ミネラル代謝研究・臨床における国内外の動向 THE BONE (2018) 31, 441-448
24. 田中良哉 関節リウマチの治療法の進歩 CLINICAL CALCIUM （2017） 28, 395-401 25. 鳥本桂一、岡田洋右、田中良哉 2 型糖尿病と血管内皮機能障害 産業医科大学雑誌 (2018) 40, 65-75 26. 田中良哉 骨免疫学と新たな治療への展望 骨髄由来間葉系幹細胞を用いた骨関節疾患治療 THE BONE （2017） 31, 211-216 27. 岡田 洋右、西村 理明 血糖変動を取り巻く未来 CGM による血糖変動の把握、その先へ Calm （2017） 4, 85-91 28. 成澤 学、岡田洋右 CGM の「イロハ」教えます 実践編 CGM のある一例からみる治療戦略のディシジョンメイキング Calm （2017） 4, 63-66 29. 新生 忠司、 岡田 洋右、 成澤 学、 鳥本 桂一、 田中 良哉 重症成人成長ホルモン分泌不全症における成長ホルモン補充療法による治療 1 年後の糖代謝への影響に関 する検討 Diabetes Frontier （2017） 28, 594-598 30. 五嶋由紀子、岡田洋右、成澤 学、鳥本桂一、田中良哉 リラグルチドのインスリン併用療法における有効性および安全性の検討 Diabetes Frontier （2017） 28, 457-460 31. 河邊 明男、中野 和久、田中 良哉 【関節リウマチのプレクリニカルステージ】 エピジェネティクスからみた RA の発症要因 Keynote R・A （2017） 2, 57-60 32. 岡田洋右 【骨粗鬆症治療-最新の治療戦略】 ステロイド性骨粗鬆症に対する薬物療法 Mebio（2017） 34, 32-40 33. 中山田真吾、田中良哉 JAK 阻害薬の開発の現状と今後の展望 リウマチ科（2017） 58, 452-460
34. 久保智史、田中良哉
CORRONA レジストリーのアバタセプトとトシリズマブの comparative effectiveness study リウマチ科（2017） 58, 441-445 35. 久保智史、中山田真吾、田中良哉 関節リウマチ治療におけるバリシチニブの有用性 リウマチ科（2017） 57, 410-415 36. 中山田真吾、田中良哉 【経口抗リウマチ薬を総括する】 バリシチニブ 分子リウマチ治療（2017） 10, 197-201 37. 新生 忠司、岡田 洋右、上村 芙美、西澤 茂、田中 良哉
オクトレオチド Long Acting Release(LAR)投与により下垂体腫瘍が著明に縮小し治癒切除し得た先端巨大症一 例 産業医科大学（2017） 39, 241-245 38. 岡田洋右 2 さくさくわかる各論 7 高血糖が骨質に与える影響 糖尿病ケア（2017） 14，135-137 39. 新生忠司、岡田洋右、鳥本桂一、瓜生康平、田中良哉 心アミロイドーシスを合併した甲状腺アミロイドーシスによる粘液水腫性昏睡の1例 内科（2017）119，339-343 40. 黒住旭、岡田洋右 糖尿病治療薬が骨粗鬆症に与える影響．糖尿病と骨粗鬆症の危うい関係 月刊糖尿病（2017）9，62-69 41. 鳥本桂一、岡田洋右 今、明かされたSGLT2阻害薬の多面的作用と適正使用．SGLT2阻害薬の適する患者像とは～高齢者、腎障害 患者、非肥満患者にも適応はあるのか～ 月刊糖尿病（2017）12，28-37 42. 大塚隆史、岡田洋右、新生忠司、田中健一、田中良哉 腹痛を契機に甲状腺クリーゼを発見できた高齢者 Basedow病の１例 内科（2017）120，1006-1009
43. 鳥本桂一、岡田洋右 ポリファーマシーの問題点と解決策 ポリファーマシー各論 運動障害を有する患者に対する処方の留意点 CURRENT THERAPY（2018）36，141-145 44. 岡田洋右 新しい医療技術 持続血糖測定 整形・災害医学（2018）61，337-341 45. 上村芙美、岡田洋右、鳥本桂一、田中良哉 甲状腺機能亢進症治療前後での食後過血糖の改善をCGMで確認しえたバセドウ病の1例 Diabetes Journal（2018）46，24-29 46.杉野祥子、岡田洋右、鳥本桂一、田中良哉 ステロイドパルス3回施行後増悪再燃をきたした難治性甲状腺眼症に対してcyclophosphamideパルス療法が有 効であった1例 内科（2018）121.1245-1248
